The Zhitong Finance App learned that on Thursday, HCM.US (HCM.US) surged more than 14% to $13.75. According to the news, Hutchison Pharmaceutical announced that its subsidiary Hutchison Whampoa Pharmaceuticals (Shanghai) and a subsidiary of GlaxoSmithKline (GSK.US) have reached an exclusive development and licensing agreement, granting GlaxoSmithKline subsidiaries the right to develop and commercialize the HMPL-A830 on a global scale other than mainland China, Hong Kong, Macau and Taiwan. Clinical development will first focus on colorectal cancer, pancreatic cancer, and lung cancer indications.

Zhitongcaijing · 1d ago
The Zhitong Finance App learned that on Thursday, HCM.US (HCM.US) surged more than 14% to $13.75. According to the news, Hutchison Pharmaceutical announced that its subsidiary Hutchison Whampoa Pharmaceuticals (Shanghai) and a subsidiary of GlaxoSmithKline (GSK.US) have reached an exclusive development and licensing agreement, granting GlaxoSmithKline subsidiaries the right to develop and commercialize the HMPL-A830 on a global scale other than mainland China, Hong Kong, Macau and Taiwan. Clinical development will first focus on colorectal cancer, pancreatic cancer, and lung cancer indications.